EWY vs XBI
iShares MSCI South Korea ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.59% for EWY.
- • EWY pays a higher dividend yield (1.29%).
Side-by-side metrics
| Metric | EWY | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.59% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.29% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $21.05B | $8.30B |
YTD return | 87.18% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 2.13 | 1.09 |
P/E ratio | 23.20 | — |
Last price | $176.75 | $133.66 |
Inception | — | — |
Issuer | iShares | State Street |
EWY top holdings
| 000660.KS | SK Hynix Inc | 22.69% |
| 005930.KS | Samsung Electronics Co Ltd | 22.34% |
| 402340.KS | SK Square | 2.78% |
| 005380.KS | Hyundai Motor Co | 2.40% |
| 105560.KS | KB Financial Group Inc | 1.99% |
| 034020.KS | Doosan Enerbility Co Ltd | 1.95% |
| 009150.KS | Samsung Electro-Mechanics Co Ltd | 1.79% |
| 012450.KS | Hanwha Aerospace Co Ltd | 1.64% |
| 006400.KS | Samsung SDI Co Ltd | 1.54% |
| 055550.KS | Shinhan Financial Group Co Ltd | 1.48% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About EWY
EWY (iShares MSCI South Korea ETF) is South Korean large and mid-cap equities. Managed by iShares, the fund carries $21.0B in assets under management, an expense ratio of 0.59%, a dividend yield of 1.29%. Its largest holding is SK Hynix Inc (000660.KS), which represents 22.7% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 5.7%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.